| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 26.691 | 28.490 | 40.387 | 77.625 | 89.555 | 78.981 | 95.908 | 115.102 | 113.207 | 200.130 |
| Total Income - EUR | 26.691 | 28.601 | 40.387 | 77.807 | 89.780 | 81.249 | 96.744 | 115.103 | 121.772 | 200.132 |
| Total Expenses - EUR | 17.933 | 27.317 | 21.926 | 39.669 | 29.219 | 47.747 | 50.811 | 52.877 | 61.272 | 121.898 |
| Gross Profit/Loss - EUR | 8.757 | 1.284 | 18.461 | 38.139 | 60.561 | 33.502 | 45.933 | 62.226 | 60.500 | 78.235 |
| Net Profit/Loss - EUR | 7.969 | 998 | 17.478 | 37.362 | 59.665 | 32.944 | 45.042 | 61.190 | 59.178 | 72.231 |
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
Check the financial reports for the company - Provance Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 518 | 55 | 518 | 5.050 | 2.683 | 388 | 83 |
| Current Assets | 23.593 | 17.485 | 31.355 | 63.894 | 68.303 | 56.318 | 46.596 | 63.625 | 64.571 | 82.646 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 17.055 | 14.821 | 12.481 | 27.576 | 45.209 | 50.812 | 37.788 | 54.726 | 47.990 | 11.444 |
| Cash | 6.537 | 2.665 | 18.874 | 36.318 | 23.094 | 5.506 | 8.808 | 8.899 | 16.580 | 71.203 |
| Shareholders Funds | 4.781 | 1.053 | 17.529 | 54.570 | 59.709 | 33.015 | 45.111 | 61.260 | 59.248 | 72.300 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 18.812 | 16.432 | 13.826 | 9.842 | 8.649 | 26.804 | 8.782 | 6.597 | 6.569 | 10.429 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Provance Med Srl